Shorting stocks: High fliers Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Shorting stocks: High fliers

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Q. who wrote (539)	9/7/1998 2:11:00 PM
From: Ken Brown	Read Replies (1) of 709

John, I certainly don't want to add to that queasy HEB feeling, but that "Value Management & Research" report indicates that HEB completed Phase 3 trials, and was granted something called a "treatment IND" (Investigational New Drug). This allows them to sell Ampligen for treating severe cases of CFS, while they continue to gather more data (i.e., the larger, second Phase 3 trial they are just starting). Another way to look at it, I assume, is that they did not have convincing evidence from the initial Phase 3 trial, but the FDA is allowing them to do some real-world testing in the meantime (since the first Phase 3 didn't show any dangerous side effects). I'm no biotech guru, as I tend to stay away from them (short or long). I broke my rule this time! Any idea when that lockup ends? I couldn't find a reference to it in the 10Q or S-3 filings I looked at. We sure could use some concentrated selling to hold the lid on this one. Ken

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next